Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for obesity treatment, and whilst it affects glucose metabolism, its risk of causing hypoglycaemia varies significantly depending on whether you have diabetes and what other medications you take
The drug is not uniquely catabolic to muscle - it's an effective weight-loss tool that creates a caloric deficit, and caloric deficits cause lean mass loss when protein and resistance training aren't prioritized
The longer you took tirzepatide before stopping, the more weight you typically regain
The findings highlight a dose-dependent reduction in body weight across these doses without liver function compromise (Fig
Fernandes L, Hagen KB, Bijlsma JW, Andreassen O, Christensen P, Conaghan PG, Doherty M, Geenen R, Hammond A, Kjeken I, Lohmander LS, Lund H, Mallen CD, Nava T, Oliver S, Pavelka K, Pitsillidou I, da Silva JA, de la Torre J, Zanoli G, Vliet Vlieland TP (2013) European League Against R EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis
"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)"
